Theravance Biopharma (TBPH) Competitors

Theravance Biopharma (NASDAQ:TBPH) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.

Do insiders & institutionals believe in TBPH or BLTE?

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor TBPH or BLTE?

Theravance Biopharma received 308 more outperform votes than Belite Bio when rated by MarketBeat users. However, 97.14% of users gave Belite Bio an outperform vote while only 62.87% of users gave Theravance Biopharma an outperform vote.

Company	Underperform	Outperform
Theravance Biopharma	Outperform Votes 342 62.87%	Underperform Votes 202 37.13%
Belite Bio	Outperform Votes 34 97.14%	Underperform Votes 1 2.86%

Does the media refer more to TBPH or BLTE?

In the previous week, Theravance Biopharma had 8 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Theravance Biopharma and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.07 beat Theravance Biopharma's score of 1.01 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate TBPH or BLTE?

Theravance Biopharma presently has a consensus price target of $11.33, suggesting a potential upside of 9.29%. Belite Bio has a consensus price target of $96.67, suggesting a potential upside of 54.27%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Belite Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is TBPH or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Theravance Biopharma's net margin of -78.18%. Theravance Biopharma's return on equity of -24.79% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	-78.18%	-24.79%	-13.43%
Belite Bio	N/A	-31.94%	-30.73%

Which has more volatility and risk, TBPH or BLTE?

Theravance Biopharma has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.52, indicating that its stock price is 252% less volatile than the S&P 500.

Which has stronger valuation & earnings, TBPH or BLTE?

Belite Bio has lower revenue, but higher earnings than Theravance Biopharma. Belite Bio is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$64.38M	8.05	-$55.19M	-$1.15	-9.02
Belite Bio	N/A	N/A	-$31.63M	-$1.18	-53.10

Summary

Theravance Biopharma beats Belite Bio on 9 of the 17 factors compared between the two stocks.